Cardinal Health, Inc. 10-Q Summary: Quarter Ended December 31, 2006
Business Context and Reporting Period
This Form 10-Q covers the three and six months ended December 31, 2006. Cardinal Health, Inc. operates as a leading provider of healthcare products and services. During this period, the Company reorganized its reporting segments and reclassified substantially all of its Pharmaceutical Technologies and Services (PTS) segment to discontinued operations following a commitment to sell the business. The Company's remaining operations are reported across four segments: Healthcare Supply Chain Services (Pharmaceutical and Medical), Clinical Technologies and Services, and Medical Products Manufacturing.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Dec 31, 2006 | 6 Months Ended Dec 31, 2006 |
|---|---|---|
| Revenue | $21,784.6 | $42,722.1 |
| Gross Margin | $1,299.9 (6.0%) | $2,500.4 (5.9%) |
| Operating Earnings | $512.1 | $963.4 |
| Net Earnings (Continuing Ops) | $315.7 | $607.3 |
| Net Earnings (Total) | $739.3 | $1,010.0 |
| Diluted EPS (Total) | $1.80 | $2.45 |
| Cash from Operating Activities | N/A | $639.4 |
| Total Debt (Long-term + Current) | $3,024.7 | $3,024.7 |
| Cash and Equivalents | $1,003.3 | $1,003.3 |
Note: Total Debt calculated as Current portion of long-term obligations ($48.9M) plus Long-term obligations ($2,935.8M) as of Dec 31, 2006.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 13% for the quarter and 12% for the six-month period compared to the prior year, driven by growth in all four continuing segments, particularly the Pharmaceutical distribution business.
- Discontinued Operations Impact: Net earnings were significantly boosted by discontinued operations, which contributed $423.6 million in the quarter and $402.7 million for the six months. This includes a $425.0 million net tax benefit recognized in the second quarter related to the PTS segment divestiture.
- Profitability: Operating earnings from continuing operations rose 12% (quarter) and 17% (six months). Gross margin dollars increased, though margins remained under pressure from competitive pricing and the Alaris SE pump recall charge.
- Special Items: Total special items (restructuring, merger, litigation) were $19.6 million for the quarter and $41.8 million for the six months, compared to $14.3 million and $34.5 million in the prior year periods.
Guidance, Outlook, and Risks
- PTS Divestiture: On January 25, 2007, the Company entered an agreement to sell the PTS segment to an affiliate of The Blackstone Group for approximately $3.3 billion in cash. The sale is expected to close in the fourth quarter of fiscal 2007, generating approximately $3.1 billion in after-tax proceeds.
- Share Repurchases: The Company announced an additional $1.5 billion share repurchase program in January 2007, bringing total authorization to $4.5 billion. Proceeds from the PTS sale are intended to fund these repurchases.
- Alaris SE Pump Recall: The Company is complying with a Consent Decree regarding the recall of Alaris SE infusion pumps. A $13.5 million charge was recorded in the prior quarter; management does not believe compliance will materially affect results, though additional costs are possible.
- Legal and Regulatory: The Company is subject to an ongoing SEC investigation regarding accounting practices, with a potential $35.0 million penalty reserved. It is also facing shareholder class action lawsuits and ERISA litigation where outcomes and potential losses cannot be estimated.
- Liquidity: The Company maintains a $1.5 billion revolving credit facility (amended Jan 2007) and a $1.0 billion commercial paper program. Cash and equivalents stood at $1.0 billion as of period end.
Investor Verification Checklist
- PTS Sale Closing: Verify the final closing date and purchase price adjustments for the Pharmaceutical Technologies and Services segment sale to Blackstone.
- SEC Settlement: Monitor the finalization of the SEC settlement agreement and confirm if the reserved $35.0 million penalty is the final liability.
- Alaris Recall Costs: Track any additional costs or penalties arising from the Alaris SE pump recall and FDA compliance requirements.
- Share Repurchase Execution: Confirm the pace of share repurchases under the new $4.5 billion authorization program.
- Discontinued Operations Tax Benefit: Understand the timing of the tax expense recognition that will offset the $425.0 million tax benefit upon the final closing of the PTS sale.